China Traditional Chinese Medicine Holdings Past Earnings Performance
Past criteria checks 4/6
China Traditional Chinese Medicine Holdings's earnings have been declining at an average annual rate of -7.6%, while the Pharmaceuticals industry saw earnings growing at 5.9% annually. Revenues have been growing at an average rate of 7.3% per year. China Traditional Chinese Medicine Holdings's return on equity is 5.8%, and it has net margins of 7.1%.
Key information
-7.6%
Earnings growth rate
-7.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 7.3% |
| Return on equity | 5.8% |
| Net Margin | 7.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How China Traditional Chinese Medicine Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 18,122 | 1,285 | 7,457 | 686 |
| 30 Sep 23 | 17,909 | 1,107 | 7,280 | 647 |
| 30 Jun 23 | 17,696 | 929 | 7,102 | 608 |
| 31 Mar 23 | 16,000 | 847 | 6,331 | 610 |
| 31 Dec 22 | 14,304 | 764 | 5,559 | 612 |
| 30 Sep 22 | 15,560 | 1,090 | 6,411 | 665 |
| 30 Jun 22 | 16,815 | 1,417 | 7,262 | 717 |
| 31 Mar 22 | 17,934 | 1,675 | 7,917 | 706 |
| 31 Dec 21 | 19,053 | 1,933 | 8,572 | 694 |
| 30 Sep 21 | 17,677 | 1,897 | 7,781 | 647 |
| 30 Jun 21 | 16,300 | 1,861 | 6,990 | 600 |
| 31 Mar 21 | 15,553 | 1,762 | 6,662 | 575 |
| 31 Dec 20 | 14,806 | 1,663 | 6,334 | 550 |
| 30 Sep 20 | 14,423 | 1,562 | 6,074 | 525 |
| 30 Jun 20 | 14,039 | 1,461 | 5,814 | 500 |
| 31 Mar 20 | 14,180 | 1,525 | 5,813 | 482 |
| 31 Dec 19 | 14,321 | 1,588 | 5,813 | 464 |
| 30 Sep 19 | 13,528 | 1,563 | 5,391 | 435 |
| 30 Jun 19 | 12,735 | 1,538 | 4,970 | 406 |
| 31 Mar 19 | 11,997 | 1,488 | 4,424 | 376 |
| 31 Dec 18 | 11,259 | 1,439 | 3,877 | 347 |
| 30 Sep 18 | 10,579 | 1,386 | 3,586 | 288 |
| 30 Jun 18 | 9,900 | 1,332 | 3,295 | 230 |
| 31 Mar 18 | 9,119 | 1,251 | 3,032 | 216 |
| 31 Dec 17 | 8,338 | 1,170 | 2,768 | 202 |
| 30 Sep 17 | 7,785 | 1,123 | 2,595 | 205 |
| 30 Jun 17 | 7,233 | 1,075 | 2,422 | 208 |
| 31 Mar 17 | 6,883 | 1,021 | 2,360 | 198 |
| 31 Dec 16 | 6,533 | 967 | 2,298 | 187 |
| 30 Sep 16 | 6,010 | 880 | 2,147 | 184 |
| 30 Jun 16 | 5,487 | 794 | 1,995 | 181 |
| 31 Mar 16 | 4,598 | 670 | 1,732 | 147 |
| 31 Dec 15 | 3,709 | 546 | 1,468 | 112 |
| 30 Sep 15 | 3,271 | 509 | 1,309 | 72 |
| 30 Jun 15 | 2,833 | 471 | 1,151 | 32 |
| 31 Mar 15 | 2,742 | 444 | 1,138 | 16 |
| 31 Dec 14 | 2,650 | 417 | 1,125 | 0 |
| 30 Sep 14 | 2,384 | 370 | 999 | 0 |
| 30 Jun 14 | 2,117 | 324 | 872 | 0 |
| 31 Mar 14 | 1,756 | 261 | 725 | 0 |
| 31 Dec 13 | 1,395 | 198 | 577 | 0 |
| 30 Sep 13 | 1,233 | 183 | 489 | 0 |
| 30 Jun 13 | 1,082 | 170 | 405 | 0 |
Quality Earnings: 570 has high quality earnings.
Growing Profit Margin: 570's current net profit margins (7.1%) are higher than last year (5.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 570's earnings have declined by 7.6% per year over the past 5 years.
Accelerating Growth: 570's earnings growth over the past year (68.2%) exceeds its 5-year average (-7.6% per year).
Earnings vs Industry: 570 earnings growth over the past year (68.2%) exceeded the Pharmaceuticals industry 1.3%.
Return on Equity
High ROE: 570's Return on Equity (5.8%) is considered low.